Veeva Systems has been hammered by the AI-driven software selloff — but when you look past the stock chart, the fundamentals tell a completely different story. Zero debt, over $6 billion in cash, $1.4 billion in free cash flow, and a reverse DCF suggesting the market is pricing in only 5% growth. That seems like a very easy hurdle for Veeva to clear.
In this episode, Kasey breaks down why Veeva is far more than a boring CRM company. Built specifically for the biopharma and life sciences industry,
Veeva has embedded itself into every stage of the drug development process — from R&D and clinical trials through manufacturing compliance and global regulatory filings.
We cover:
- What Veeva actually does — the four-segment cloud stack explained
- FY2026 results: $3.2B revenue, 16% year-over-year growth
- The balance sheet: $6B+ cash, zero debt
- Free cash flow growing at a 16% CAGR on a per-share basis
- Is AI a genuine threat to Veeva — or a tailwind?
- CEO Peter Gassner's case for AI as symbiotic, not disruptive
- The real bottleneck in getting drugs to patients — and where Veeva fits
- A reverse DCF valuation walkthrough: what growth rate is actually priced in?
We lay out the full case and leave the conclusion where it belongs — with you.
Want deeper research and live discussion? Join our Semi Insider community at chipstockinvestor.com. New members can access the Discord server until April 15th.
Disclaimer: Content is for general information and educational purposes only and does not constitute specific investment advice. All investing involves risk. Nick and Kasey hold a position in Veeva Systems.